{"generic":"Ingenol Mebutate","drugs":["Ingenol Mebutate","Picato"],"mono":{"0":{"id":"jxo1s0","title":"Generic Names","mono":"Ingenol Mebutate"},"1":{"id":"jxo1s1","title":"Dosing and Indications","sub":{"0":{"id":"jxo1s1b4","title":"Adult Dosing","mono":"<ul><li><b>Note:<\/b> 0.015% gel for face and scalp; 0.05% gel for trunk and extremities<\/li><li><b>Actinic keratosis, Face and Scalp:<\/b> Apply 0.015% gel TOPICALLY to affected area once daily for 3 consecutive days; allow to dry for 15 minutes; avoid touching or washing area for 6 hours after application<\/li><li><b>Actinic keratosis, Trunk and Extremities:<\/b> Apply 0.05% gel TOPICALLY to affected area once daily for 2 consecutive days; allow to dry for 15 minutes; avoid touching or washing area for 6 hours after application<\/li><\/ul>"},"1":{"id":"jxo1s1b5","title":"Pediatric Dosing","mono":"Safety and effectiveness not established in patients younger than 18 years "},"3":{"id":"jxo1s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Actinic keratosis, Face and Scalp<\/li><li>Actinic keratosis, Trunk and Extremities<\/li><\/ul>"}}},"3":{"id":"jxo1s3","title":"Contraindications\/Warnings","sub":[{"id":"jxo1s3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jxo1s3b10","title":"Precautions","mono":"<ul><li>application to skin not healed after previous drug or surgical treatment is not recommended<\/li><li>eye disorders (eg, severe eye pain, eyelid edema, eyelid ptosis, periorbital edema) may occur after accidental exposure to eye<\/li><li>skin reactions of the treated area, severe (eg, erythema, crusting, swelling, vesiculation\/postulation, and erosion\/ulceration), have been reported<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jxo1s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jxo1s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jxo1s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Application site infection (8%), Application site irritation (4%), Application site pain (2% to 15%), Crust on skin (any grade, 74% to 80%; grade 4, 4% to 6%), Erythema (any grade, 92% to 94%; grade 4, 19% to 24%), Peeling of skin (any grade, 85% to 90%; grade 4, 8% to 9%), Pruritus, Application site (8%), Pustular vasculitis (any grade, 44% to 56%; grade 4, 1% to 5%), Superficial ulcer of skin (any grade, 26% to 32%; grade 4, up to 1%), Swelling of skin (any grade, 64% to 79%; grade 4, 3% to 5%)<\/li><li><b>Neurologic:<\/b>Headache (2%)<\/li><li><b>Ophthalmic:<\/b>Periorbital edema (3%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (2%)<\/li><\/ul>"},"6":{"id":"jxo1s6","title":"Drug Name Info","sub":{"0":{"id":"jxo1s6b17","title":"US Trade Names","mono":"Picato<br\/>"},"2":{"id":"jxo1s6b19","title":"Class","mono":"Dermatological Agent<br\/>"},"3":{"id":"jxo1s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jxo1s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jxo1s7","title":"Mechanism Of Action","mono":"The mechanism by which ingenol mebutate induces cell death in actinic keratosis lesions is not known.<br\/>"},"8":{"id":"jxo1s8","title":"Pharmacokinetics","sub":{"0":{"id":"jxo1s8b23","title":"Absorption","mono":"Bioavailability, Topical: negligible <br\/>"},"2":{"id":"jxo1s8b25","title":"Metabolism","mono":"Hepatic: extensive in vitro <br\/>"}}},"9":{"id":"jxo1s9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>Note: 0.015% gel for face and scalp; 0.05% gel for trunk and extremities<\/li><li>Spread contents of single-dose tube evenly over affected area (contiguous area up to 25 cm(2))<\/li><li>Allow to dry for 15 minutes; do not touch or wash area for 6 hours after application<\/li><\/ul>"},"10":{"id":"jxo1s10","title":"Monitoring","mono":"no specific monitoring has been determined <br\/>"},"11":{"id":"jxo1s11","title":"How Supplied","mono":"<b>Picato<\/b><br\/>Topical Gel\/Jelly: 0.015 %, 0.05 %<br\/>"},"13":{"id":"jxo1s13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid contact with the periocular area. If accidental exposure occurs, flush eyes with water and seek immediate medical care.<\/li><li>This drug may cause local skin reactions (erythema, flaking\/scaling, crusting, swelling, vesiculation\/pustulation, and erosion\/ulceration); pain, pruritus, irritation, or infection of the application site; headache; or nasopharyngitis.<\/li><li>Advise patient to wash their hands immediately after applying drug and avoid transfer of drug to other areas, or to another person.<\/li><li>Instruct patient to allow gel to dry for 15 minutes after application; avoid washing and touching the treated area, or participating in activities that cause excessive sweating, for 6 hours after treatment; may wash the area with mild soap after 6 hours.<\/li><li>Instruct patient not to apply drug on skin that is not healed from any previous drug or surgical treatment.<\/li><\/ul>"}}}